Form 4: Acrivon Therapeutics Chief Accounting Officer Sells Shares to Cover Tax Obligations

Katharine Peterson, Chief Accounting Officer of Acrivon Therapeutics, sold 99 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Katharine Peterson, the Chief Accounting Officer of Acrivon Therapeutics, sold 99 shares of the company's common stock on November 14, 2024.
• The sale was executed at a price of $7.92 per share.
• This transaction was to cover mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following the transaction, Ms. Peterson directly owns 4,535 shares of Acrivon Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes and does not indicate any positive or negative sentiment towards the company's performance or future prospects.

Industry Context

This is a routine transaction for company insiders to cover tax obligations related to stock-based compensation. It is a common practice and does not necessarily indicate a change in the executive's outlook on the company.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• Many companies use restricted stock units as part of their compensation packages, which often trigger tax liabilities upon vesting.
• The number of shares sold is relatively small compared to the total shares owned by the executive, which is typical in these types of transactions.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a small sale by an executive to cover tax obligations.

Key Dates

Keywords

Acrivon Therapeutics, insider trading, stock sale, Form 4, Katharine Peterson, tax withholding, restricted stock units